CURRICULUM VITAE ET STUDIORUM
Prof MASSIMILIANO AGOSTINI

PERSONAL DATA

Family name	AGOSTINI Massimiliano
Date of birth	20 January 1972
Place of birth	Terni, Italy
Citizenship	Italian
Address	Dept. Experimental Medicine University of Rome "Tor Vergata" via Montpellier, 1 00133 Roma, Italy

ORCID identifier 0000-0003-3124-2072
Public record http://orcid.org/0000-0003-3124-2072
Scopus Author ID: 7005322176
Researcher ID: G-9579-2014 http://www.researcherid.com/rid/G-9579-2014

PRESENT POSITION
Associate Professor, Molecular Biology, University of Rome "Tor Vergata", Italy

EDUCATION
1997 Degree in Chemical and Pharmaceutical Technology
1998 Pharmacist license, state of Italy
2006 PhD in Clinical and Experimental Pharmacology

CAREER HISTORY
1997-1999 Visiting Fellow Section of Pharmacology, School of Medicine, University of Perugia
1999-2001 Fellowship Section of Pharmacology, School of Medicine, University of Perugia
2005-2006 Research Assistant Section of Pharmacology, School of Medicine, University of Perugia
2006-2007 Research Assistant Section of Pharmacology, School of Medicine, University of Perugia
2007-2011 Career Development Fellow, MRC Toxicology Unit, UK
2014-2014 Visiting Scientist, at The Campbell Family Institute for Breast Cancer Research, Toronto, Canada
2011-2014 Senior Investigator, MRC Toxicology Unit, UK
2014 to 2019 Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK

MEMBERSHIP
2002 Italian Society of Pharmacology

TEACHING ACTIVITIES

2015-Present Metabolomics and Transcriptomics II level Master, Personalized Nutrition: Molecular and Genetic bases, University of Rome Tor Vergata
2016-Present Cancer Metabolism I level Master, Nutrition and Cosmesis, University of Rome Tor Vergata
2016-2020 Biochemistry and Molecular Biology International Medical School University of Rome Tor Vergata
2017-2020 Molecular Biology Medicine and Surgery, University of Rome Tor Vergata
2017-Present Molecular Biology Residency in Infection Disease University of Rome Tor Vergata, Italy
2019-Present Molecular Biology Residency in Endocrinology and Metabolic Diseases Virology University of Rome Tor Vergata
2019-Present Molecular Biology Residency in Microbiology and Virology University of Rome Tor Vergata
2020 Biochemistry School of Pharmacy University of Rome Tor Vergata
2020 Molecular Biology International Medical School University of Rome Tor Vergata
2021-2022 Scienze della nutrizione umana (Metabolomics**)**
2023-Present Scienze della nutrizione umana (Nutrition, inflammation and cancer**)**
2023-Present Biochemistry and Molecular Biology Residency in Cardiovascular Diseases
2024-Present Molecular Biology Residency in Pathological Anatomy

EDITORIAL ACTIVITY

2014-2019 Editorial board of *Molecular & Cellular Oncology*
2011-2023 Receiving Editor *Cell Death & Disease*
2011-Present Editorial board as Review Editor of Frontiers in Oncology's speciality section *Frontiers in Cancer Molecular Targets and Therapeutics*
2022-Present Editorial Board of *Cancers*
2023-Present Deputy Editor *Cell Death & Disease*

Ad hoc Referee:
Cell Death & Disease, Cell Death and Differentiation, Frontiers in Cancer, Molecular and Cellular Oncology, Molecular Neurobiology, Oncogene, Oncotarget, Cell Cycle, FEBS Journal, Scientific Reports, Journal of Cellular Biochemestry, Molecular Oncology, FASEB Journal, Journal of Human Genetics, Biology Direct

RESEARCH INTEREST

MA is mainly interested in the characterization of transgenic mice with genetic alterations in the p53 family genes and their targets to understand their effect on development and cancer. In particular, he aims to investigate the role of the transcription factor ZNF750 (transcriptionally regulated by p63) in tumorogenesis by using combing *in vitro* and *in vivo* models combined with system biology (transcriptomics, proteomics and metabolomics). Currently, MA is mainly involved on:
1) Dissecting *in-vivo* functions of specific p53-family gene isoforms in tumorigenesis.
2) Targeting lipid metabolism for cancer treatment
3) To identify *in-vivo* functions of ZNF750 in development, physiology and tumorigenesis by using genetically modified animals.

PUBLICATION

Scientific Papers	86 (First Author: 20; Corresponding Author: 14)		
Citations	7886 (Scholar)	5285 (ISI)	5694 (Scopus)
h-Index	46 (Scholar)	38 (ISI)	40 (Scopus)

Most representative publication

1) Zhu M, et al **Agostini M** Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype *Discov Oncol*. 2024 Jan 16;15(1):10.
2) Peng F, et al Alleviating hypoxia to improve cancer immunotherapy *Oncogene* 2023 Dec;42(49):3591-3604
3) Butera A*, **Agostini M***, et al ZFP750 affects the cutaneous barrier through regulating lipid metabolism *Science Advances* 2023 Apr 28;9(17). (*) Co-First Author
4) Vitale I, et al. Apoptotic cell death in disease—Current understanding of the NCCD 2023 *Cell Death Differ* 2023 May;30(5):1097-1154
5) **Agostini M***, et al Targeting lipid metabolism in cancer: neuroblastoma *Cancer Metastasis Rev* 2022 Jun 10. doi: 10.1007/s10555-022-10040-8 (*) Corresponding Author
6) Rugolo F, et al and **Agostini M** The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome *Oncogene* 2021 Sep;40(38):5741-5751
7) Velletri T et al. Loss of p53 in mesenchymal stem cells promotes alteration of bone remodelling through negative regulation of osteoprotegerin. *Cell Death Differ* 2020 Online ahead of print.
8) Amelio I et al The p73 C-terminus directs hippocampal development *Proc Natl Acad Sci U S A* 2020 117 (27) 15694-15701
9) Cassandri M et al. **Agostini M** and Melino G ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes *Oncogene* 2020 **39,** 4331–4343
10) **Agostini M**, et al p73 regulates primary cortical neurons metabolism: a global metabolic profile *Mol Neurobiol.* 2017 2017 May 6. doi: 10.1007/s12035-017-0517-3.
11) **Agostini M**, et al Metabolic reprogramming during neuronal differentiation *Cell Death Differ* 2016 Sep 1;23(9):1502-14.
12) Viticchiè G, et al ΔNp63 supports aerobic respiration through hexokinase II *Proc Natl Acad Sci USA*. 2015 Sep 15;112(37):11577-82.
13) Amelio I, et al. Serine and glycine metabolism in Cancer *Trends Biochem Sci* 2014 Apr;39(4):191-198.
14) Inoue S, et al. TAp73 is required for spermatogenesis and the maintenance of male fertility. *Proc Natl Acad Sci USA*. 2014;111(5):1843-8.
15) Niklison-Chirou MV, et al. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75NTR *Proc Natl Acad Sci U S A* 2013;110 (47):18952-7.
16) Tucci P*, **Agostini M***, et al. Loss of p63 and its miR-205 target results in enhanced cell migration and metastasis in prostate cancer. *Proc Natl Acad Sci U S A.* 2012 109(38):15312-7. (*) Co-First Author
17) He Z, et al. p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. *Cell Death Differ.* 2013 Oct;20(10):1415-24.
18) Amelio I, et al. p73 regulates serine biosynthesis in cancer. *Oncogene*. 2013. doi: 10.1038/onc.2013.456.
19) **Agostini M**, et al. miR-34a regulates neurite outgrowth, spinal morphology and function. *Proc Natl Acad Sci U S A.* 2011;108(52):21099-104.
20) **Agostini M**, et al. Neuronal differentiation by TAp73 is mediated by miR-34a regulation of synaptic protein targets. *Proc Natl Acad Sci U S A*. 2011;108(52):21093-8.